After 30 Years, a Missing Childhood Cat Still Haunts One Family’s Search for Closure

Nearly three decades have passed since Peppy, my childhood cat, vanished without a trace. I can still summon a few snapshots of her—how her fur felt under my hand as she purred, her talent for getting stranded in trees, and one notorious bathroom mishap involving my baby sister’s cot. But what I remember most clearly is the day she didn’t come home. I was 10, and I spent hours combing fields and nearby woods until dusk, then taped up missing posters and waited. We never found her. The finality of that loss was crushing—and unavoidable.

Today, a growing corner of biotechnology is built around the idea that pet owners don’t have to accept “unavoidable” so readily. New products and services aim to extend the time people have with their animals, and the menu is expanding: drugs designed to slow or prevent age-related decline, cloning marketed as a way to “hold on,” and cryonics that promises—someday, theoretically—to reverse death itself.

The demand is real, and companies are moving quickly to meet it. Loyal, one of the best-known entrants in the pet longevity space, is developing three potential anti-aging drugs for dogs. One of its candidates is being tested for metabolic health benefits in roughly 1,300 pet dogs across the United States. Other efforts target both the diseases that accumulate with age—such as obesity and osteoarthritis—and the underlying aging process. Cats are not being left out: at least one company is pursuing longevity medicines specifically for domesticated felines.

If medicine could have reduced Peppy’s odds of developing something like diabetes or arthritis, I would have been eager to try it. Preventing suffering and improving the quality of an animal’s later years feels like an extension of ordinary veterinary care. But beyond that point—where “help your pet age better” becomes “defeat death”—my comfort level drops.

Cloning is one option now marketed to grieving owners seeking something close to a do-over. The process generally involves taking DNA from the original animal, inserting it into an egg cell from another animal of the same species, and implanting the resulting embryo into a surrogate. The approach famously produced Dolly the sheep—born the year before Peppy disappeared—and has since been used in a range of mammals, including cattle, horses and ferrets, as well as cats and dogs.

In the United States, Viagen Pets offers cloning services for cats and dogs, charging about $50,000 per animal. The result is not a carbon copy in personality or experience; it is a genetic twin. Yet the appeal is understandable, and the company’s own marketing frames cloning as a way to keep a bond intact.

Lori Kogan, a professor of clinical sciences at Colorado State University who studies human–animal relationships, argues that the practice can be a legitimate form of comfort. Human societies have formal rituals for mourning people—funerals, bereavement leave, sympathy gifts—but comparatively little for pet loss. That can leave owners experiencing “disenfranchised grief,” she notes: sorrow that feels unacknowledged and isolating. If cloning eases that pain, she asks, why condemn it?

Still, the calculus may be different for children. For many, losing a pet is the first encounter with death. As brutal as it was, Peppy’s disappearance helped shape my understanding of permanence and loss. I’m not sure I would want my own children to absorb the idea that death is negotiable—or that an individual can simply be reproduced.

That question becomes even sharper with cryonics. For a fee, a small number of companies will cool dead pets to extremely low temperatures and store them for years, decades, or longer. The premise is explicitly future-oriented: that breakthroughs not yet invented could one day restore life and fix whatever caused death. Alcor, a cryonics facility in Arizona, is already storing the remains of hundreds of pets alongside human clients, and recently reported preserving a sugar glider—its first of that species.

Why it matters

Pets are family for many households, and a fast-growing industry is offering scientific tools to stretch—or blur—the boundaries of pet mortality. Longevity drugs could reshape veterinary medicine by focusing on aging itself, not just individual diseases, while cloning and cryonics raise harder ethical and psychological questions about grief, identity, and expectations. What happens next will depend on clinical trial results, regulatory decisions, and how society chooses to define “care” versus “replacement.”